Funding

Syndax Pharmaceuticals Grabs $80M

63 Views

What does Syndax Pharmaceuticals do?

Syndax Pharmaceuticals, is a clinical stage bio pharmaceutical company which is developing entinostat as a combo therapy for multiple cancer indications. This is company is focused on an HDAC inhibitor for solid tumors and hematological tumors. This is a late stage bio pharmaceutical company which leverages on the recent scientific insights on its lead- entinostat, a therapeutic candidate in the emerging field of immuno-oncology. Because of its distinctive mechanism and pre-clinical and clinical activity observed to date, the company believes entinostat holds a good promise as a combo therapy for a wide range of cancers.

 

How much Syndax Pharmaceuticals was funded?

Syndax Pharmaceuticals raised $80M in Series C funding on August 24, 2015 from Delos Capital (Lead), Arrowpoint Partners, Fidelity Management & Research (Lead), Cormorant Asset Management, BioMed Ventures, Domain Associates, Forward Ventures, EcoR1 Capital, Jennison Associates, OrbiMed, MPM Capital, RusnanoMedInvest, Top Tier Capital Partners, Tavistock Life Sciences

Previous funding

  • $24M in Venture round on June 15, 2015
  • $4.9M in Debt Financing on September 18, 2014
  • $1.7M in Venture round on February 13, 2014
  • $26.6Min Series B funding on August 27, 2013 from Domain Associates, Partner: Dennis Podlesak, MPM Capital Partner: Kim P. Kamdar, Forward Ventures and RusnanoMedInvest
  •  $6M in Debt Financing on April 5, 2010
  • $9Min Series A funding on March 16, 2010 from Avalon Ventures, Pappas Ventures Partner: Artthur M. Pappas, Forward Ventures, Domain Associates Partner: Dennis Podlesak, MPM Capital Partner: Kim P. Kamdar

What is next for Syndax Pharmaceuticals?

The funding will be used for continued development of Syndax’s product candidate, entinostat.

More about Syndax Pharmaceuticals

Syndax Pharmaceuticals was founded in 2005 by Peter Ordentlich. It has its headquarters in Waltham, MA. This is a biopharmaceutical company which is developing a combination therapy for multiple indications of cancer.

 

Related Posts